

1 **Title:** Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2
2 Antibodies

3
4 **Authors:** Keenan O. Hogan,^a MD, Dave Klippel,^a BS, Fred V. Plapp,^a MD PhD, Rachael M.
5 Liesman,^a PhD

6 ^aDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center,
7 Kansas City, Kansas, USA

8
9 **Corresponding Author:**

10 Rachael Liesman

11 Department of Pathology and Laboratory Medicine

12 3901 Rainbow Boulevard, Kansas City, KS 66160

13 Email: rliesman@kumc.edu

14 Telephone: (913) 588-1101

15 Fax: (913) 588-8780

16
17 **Funding:** This research did not receive any specific grant from funding agencies in the public,
18 commercial, or not-for-profit sectors.

19
20 **Declaration of Interest:** None.

21
22 **Brief Title:** Evaluation of Serologic Assays for SARS-CoV-2

23
24 **Key words:** SARS-CoV-2; Serology; Immunoassays; Diagnostic Accuracy

25 **Abstract**

26 *Background and aims*

27 Serologic assays for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-
28 CoV-2) antibodies are being developed and approved rapidly with limited external validation.
29 Accurate diagnostics are an essential component to pandemic management and public health.

30

31 *Materials and methods*

32 Residual serum samples (N=113) from patients who were evaluated for SARS-CoV-2 infection
33 status by polymerase chain reaction (PCR) were retrospectively tested in parallel across three
34 automated SARS-CoV-2 serologic assays: Liaison SARS-CoV-2 S1/S2 IgG, Elecsys anti-SARS-
35 CoV-2 total antibody, and Access SARS-CoV-2 IgG.

36

37 *Results*

38 Testing of 51 PCR-positive and 62 PCR-negative patients demonstrated qualitative inter-test
39 agreement of 96% overall, 100% in PCR-negative patients, 88% in early positive samples (0-13
40 days post positive PCR), and 100% in convalescent samples (14+ days post positive PCR).
41 Calculated kappa values for paired inter-test agreement ranged 0.93-0.96. Compared to PCR,
42 overall percent positive agreement ranged from 82-86% (100% for convalescent samples) and
43 percent negative agreement was 100% for each assay.

44

45 *Conclusion*

46 This study demonstrates high diagnostic accuracy and inter-test agreement for three automated
47 SARS-CoV-2 serologic assays. External validation of serologic assays is critical to ensure
48 diagnostic accuracy and appropriate utilization of critical resources.

49 **1. Introduction**

50 Documented cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exceeded
51 12 million by July 12, infecting individuals from 213 countries/regions and killing more than
52 560,000 [1]. Management of the coronavirus disease 2019 (COVID-19) pandemic relies on
53 accurate diagnostics, routinely provided by viral RNA detection through reverse transcriptase
54 polymerase chain reaction (RT-PCR) and antibody detection through immunoassays. Although
55 seroconversion has been detected as early as 4 days post symptom onset, PCR remains the
56 current standard for identification of acute infection [2-3].

57 Infectious disease and microbiology organizations recommend targeted use of serologic assays
58 for epidemiologic surveillance, identification of potential convalescent plasma donors, and
59 evaluation of experimental vaccine efficacy [4-5]. As of the writing of this manuscript, the Food
60 and Drug Administration (FDA) has issued emergency use authorization for 25 different
61 serology assays [6]. These assays vary significantly in methodology, antibody targets, and
62 manufacturer validation with few published peer-reviewed studies available for independent
63 performance evaluation.

64 In this study, we assessed the performance characteristics of three automated SARS-CoV-2
65 serologic immunoassays using divided serum samples from patients with positive and negative
66 SARS-CoV-2 PCR results: Liaison SARS-CoV-2 S1/S2 IgG, Elecsys anti-SARS-CoV-2 total
67 antibody, and Access SARS-CoV-2 IgG. We hypothesized that parallel testing would
68 demonstrate good qualitative agreement and high negative and positive percent agreement
69 (>98%).

70

71 **2. Material and Methods**

72 *2.1 Specimen Collection*

73 Between April 15 and June 1, 2020, residual serum samples ordered for routine medical
74 management of inpatients at the University of Kansas Hospital were retrospectively collected.
75 Samples were collected for two groups: (1) serum samples from patients who tested positive for
76 SARS-CoV-2 by an RT-PCR assay, and (2) serum samples from randomly selected patients who
77 had tested negative for SARS-CoV-2 by an RT-PCR assay within 48 hours prior to collection.
78 SARS-CoV-2 diagnostic testing was performed using a commercially available FDA EUA RT-
79 PCR assay. Briefly, nasopharyngeal swabs collected in either UTM or PBS were tested with the

80 Abbott RealTime SARS-CoV-2 assay (Abbott Diagnostics Inc, Scarborough, ME), performed on
81 the Abbott m2000 instrument, or the Simplex COVID-19 Direct assay (DiaSorin Molecular
82 LLC, Cypress CA), following manufacturer's instructions.

83 Residual serum samples were centrifuged, aliquoted, and frozen at -30 °C for 1 to 46 days.

84 Samples were sequentially thawed and maintained at 2-8 °C for \leq 14 days prior to testing.

85 Patient medical records were reviewed to determine sex, age, and the date of first positive

86 SARS-CoV-2 RT-PCR test. Samples were grouped by number of days after the first positive

87 molecular result into 3 pre-specified categories: 0-6 days, 7-13 days, 14+ days. All available

88 serum samples from PCR-positive patients and randomly selected PCR-negative patients that

89 were older than 18 years with adequate residual volume for parallel testing were included.

90 Samples for a single PCR-positive patient from sequential days were combined when required

91 for adequate testing volume, as long as the combined samples fell within the same pre-specified

92 category. Clinical Laboratory Scientists were not specifically blinded to the clinical status or

93 PCR results of the patients. This study was approved by the University of Kansas Medical Center

94 institutional review board prior to testing.

95 *2.2 Serologic Assays*

96 Table 1 provides a breakdown of key attributes for each serologic assay. The Elecsys anti-SARS-

97 CoV-2 antibody test (Roche Diagnostics, Rotkreuz, Switzerland) is a double antigen sandwich

98 electro-chemiluminescence immunoassay that detects total antibody against the nucleocapsid (N)

99 antigen and is performed on the Cobas e801 immunoassay analyzer. Testing was performed in

100 accordance with manufacturer's instructions. The patient sample is incubated with biotinylated

101 SARS-CoV-2 recombinant N antigen labeled with a ruthenium complex. Streptavidin-coated

102 magnetic microparticles are added and the antigen-antibody-antigen complex binds to the solid

103 phase by interaction of biotin with streptavidin. Microparticles are magnetically captured onto

104 the surface of an electrode where application of a voltage induces chemiluminescence which is

105 measured by a photomultiplier. Results are expressed as a cut-off index (COI). A result of <1.0 is

106 considered non-reactive while a result of ≥ 1.0 is considered reactive.

107 The Liaison SARS-CoV-2 S1/S2 assay (DiaSorin S.p.A., Saluggia, Italy) detects IgG antibody

108 against the S1 and S2 subunits of the spike protein using a chemiluminescent indirect

109 immunoassay (CLIA) and is performed on the DiaSorin Liaison XL immunoassay analyzer.

110 Testing was performed in accordance with manufacturer's instructions. Patient serum is

111 combined with magnetic particles coated with biotinylated recombinant S1/S2 antigen, which
112 binds to SARS-CoV-2 antibody, if present. Following incubation, isoluminol labeled mouse anti-
113 human IgG are added, which will bind to the SARS-CoV-2 antibody. The amount of isoluminol
114 antibody conjugate is determined as a flash chemiluminescence reaction and reported in arbitrary
115 units per milliliter (AU/mL). A result of <15 is considered negative while a result of ≥ 15.0 is
116 considered positive.

117 The Access SARS-CoV-2 IgG assay (Beckman Coulter, Inc., Minnesota, USA) is a
118 chemiluminescent indirect immunoassay that detects IgG antibody to SARS-CoV-2 and is
119 performed on the Beckman Coulter DXI 800 immunoassay analyzer. Testing was performed in
120 accordance with manufacturer's instructions. A sample is incubated with paramagnetic particles
121 coated with recombinant SARS-CoV-2 protein specific for the receptor binding domain (RBD)
122 of the S1 Protein. Monoclonal anti-human IgG alkaline phosphatase conjugate is added to bind
123 IgG antibodies captured on the particles. Light generated by chemiluminescent substrate is
124 measured with a luminometer. The light signal is compared to the cut-off value and is expressed
125 as a signal to cutoff ratio (S/CO). A result of <0.8 is interpreted as non-reactive while a result of
126 ≥ 1.0 is considered reactive. Results between 0.8 and 1.0 (inclusive) are considered equivocal.

127

128 *2.3 Statistics*

129 Each sample represented a unique patient. For the purposes of analysis, equivocal results were
130 treated as negative and combined samples were represented by the day farthest from the patient's
131 positive PCR test. Percent positive agreement (PPA) and percent negative agreement (PNA)
132 were calculated with 95% confidence intervals (CI) using the Clopper-Pearson exact method for
133 sensitivity and specificity and stratified by length of time from positive PCR test. Paired inter-
134 test agreement was calculated with 95% CI and standard error (SE) using Fleiss kappa. Level of
135 agreement was pre-specified as almost perfect (0.81-0.99), substantial (0.61-0.80), moderate
136 (0.41-0.60), fair (0.21-0.40), and slight (0.00-0.20). Statistical analysis was performed using
137 GraphPad Prism 8 statistics software (San Diego, USA).

138

139 **3. Results**

140 *3.1 Patient Demographics and Specimen Properties*

141 Fifty-one specimens from unique PCR-positive patients and 62 specimens from unique PCR-
142 negative patients were available for antibody testing. Table 2 describes patient demographics
143 stratified by PCR status. Patients were 60% female with a median age of 59 years (range: 19-92).
144 Date of symptom onset was not routinely documented so patients were grouped temporally by
145 the period between the first positive PCR result and serology specimen collection. Each
146 temporal group contained 17 specimens. The number of days post positive PCR ranged from 1-
147 45 days overall (median: 9) with a median of 5, 9, and 18 for 0-6 days, 7-13 days, and 14+ days,
148 respectively. Samples were combined for 14 patients 0-6 days, 3 patients 7-13 days, and 2
149 patients 14+ days.

150

151 *3.2 Diagnostic Accuracy*

152 Of 113 patients, there was consensus between the platforms in 96% (41 positive and 68
153 negative). There was 100% consensus in the convalescent positive samples (14+ days post
154 positive PCR) and negative samples but only 88% consensus in early positive samples (0-13
155 days post positive PCR). The only equivocal result was returned by the Beckman assay on a
156 single non-consensus sample. Table 3 details the results of each assay compared to PCR with
157 diagnostic accuracy and estimates of precision. No false positive results were detected and the
158 PNA was calculated at 100% for each platform. Convalescent positive samples also
159 demonstrated zero false negative results for a calculated 100% PPA. The PPA ranged from 59-
160 94% for the early positive samples.

161 Two patient specimens were reported as negative by at least 1 platform in the 7-13 days post
162 positive PCR group and both specimens were collected at 7 days. One tested negative by all
163 three platforms and review of the medical record revealed the patient was receiving
164 immunosuppressive therapy following renal transplantation. The second patient tested positive
165 on the Roche and Beckman platforms and negative on the DiaSorin platform. This patient was
166 moderately symptomatic with an elevated lactate and required supplemental oxygen but not
167 intubation during their disease course. This result may have represented early seroconversion as
168 the patient was 8 days post symptom onset with low-positive reactivity for the Roche and
169 Beckman assays (14.1 COI and 11.9 S/CO, respectively) and high-negative reactivity for the
170 DiaSorin assay (11.3 AU/mL).

171 Eight patient samples collected 0-6 days post positive PCR demonstrated at least one negative
172 serology result. The samples ranged from 1-6 days post positive PCR (median: 4). Out of the 8
173 samples, 5 were consensus negative, 1 was reactive by Roche alone, 1 was reactive by Beckman
174 alone, and 1 was reactive by DiaSorin and Beckman.

175

176 *3.3 Assay Comparison*

177 Direct comparison of the three assays is detailed in Table 4. Calculated kappa values for inter-
178 test agreement between Roche/DiaSorin, Roche/Beckman, and DiaSorin/Beckman were 0.94,
179 0.93, and 0.96, respectively. The confidence interval for each measure was within the bounds of
180 near perfect agreement and included perfect agreement (1.00).

181

182 **4. Discussion**

183 *4.1 Comparative Analysis*

184 This study describes high PNA and temporally dependent PPA for three automated SARS-CoV-
185 2 serologic assays in an independent evaluation using an inpatient cohort verified by PCR. The
186 results of this study confirm the conclusions of the systematic review by La Marca, et al. in
187 which they suggest the choice of serology assay should be made by individual labs based on
188 experience with the manufacturer, expected workflow and volume, and thoroughness of assay
189 guidance and validation [7]. They report on 49 serology studies primarily conducted in China
190 with a range of 78-100% and 0-100% for specificity and sensitivity, respectively.

191 Two peer-reviewed articles and three studies released as pre-prints specifically reported on the
192 accuracy of the DiaSorin SARS-CoV-2 serologic assay in comparison to PCR, with a range of
193 96.8-100% for specificity and 77.8-95.7% for sensitivity in convalescent patients [8-12]. With
194 100% PNA and 100% PPA in the convalescent group, this study describes a more favorable
195 diagnostic accuracy. One of the studies provided the median positive quantitative results for
196 comparison, which ranged from 8-96.3 AU/mL, with 96.3 AU/mL representing their most
197 acutely ill subjects [11]. In comparison, the median positive result in this study was 190 AU/mL,
198 which may suggest our high PPA is a consequence of high patient acuity. Correlation between
199 disease severity and antibody titer and detection has been reported [13-14]. However, direct
200 comparison of the quantitative results from these qualitative assays is limited in significance,

201 especially given the heterogeneity in study design and reporting as identified in a recent
202 Cochrane review [15].
203 Median negative results were comparable across the studies (below the limit of detection to 5.7
204 AU/mL), but two of the studies included pre-pandemic cohort samples of greater than 1000
205 patients. The difference in sampling likely explains the discordance in reported specificity.
206 Additionally, two of these studies and an additional study released as a pre-print report on the
207 Roche assay with a range of 98-99.7% and 89.2-100% for specificity and sensitivity,
208 respectively, and similar comparisons to this study may be drawn [10,12,16].
209 To our knowledge, no study has reported independent evaluation of the Beckman assay
210 diagnostic accuracy. With kappa values of 0.93 and 0.96 in comparison to the Roche and
211 DiaSorin assay, respectively, 100% PNA, and 100% PPA in convalescent specimens, we
212 demonstrate no significant difference in the performance between these three platforms.
213 Including several weak positive results, seroconversion was detected across all PCR-positive
214 patients by day 8 as shown in Figure 1. Although the time of symptom onset for our patient
215 population was not routinely recorded, our data likely coincides with the reported median
216 seroconversion for total antibody and IgG antibody alone of 11 and 14 days post symptom onset,
217 respectively [17]. Although the Roche assay detects total antibody and DiaSorin and Beckman
218 assays detect IgG antibody, there was no identifiable difference in the detection of early
219 seroconversion.
220 Clinical context will be essential in identifying pre-test probabilities based on local
221 seroprevalence, patient symptomatology, and stage of disease course [18]. Although our
222 population did not include any false positive results, testing of large pre-pandemic cohort
223 samples have reported variable specificity. The use and interpretation of serologic assays is also
224 complicated by the continued uncertainty of antibody durability and the relationship between
225 positive serologic testing and the presence of neutralizing antibodies [14]. One study comparing
226 the DiaSorin assay to a viral microneutralization test reported a sensitivity and specificity of
227 43.8% and 94.9%, respectively, for 70 PCR-positive patients and 81 pre-pandemic patients [19].
228 Overall, evidence is limited and laboratories offering serology testing for SARS-CoV-2 must
229 make these limitations clear. For patients with a complicated medical history or atypical
230 presentation, antibody testing may provide important diagnostic information. It has been reported
231 that overall sensitivity for serology is greater than nucleic acid testing for SARS-CoV-2 starting

232 day 8 after symptom onset and combined serology and RT-PCR testing provides significantly
233 improved sensitivity compared to RT-PCR alone early in the disease course [17,20].

234

235 *4.2 Limitations*

236 This study has several limitations. The testing of a relatively small number of retrospective
237 convenience samples is at risk for confirmation bias and underpowered calculations.
238 Specifically, our cohort of inpatients likely includes a greater average patient acuity, which
239 would tend to inflate sensitivity. This may also increase the number of false positive results,
240 which was not identified. In the absence of thorough chart review for the PCR-negative cohort,
241 the presence of confounding factors contributing to an artificially high true negative rate cannot
242 be excluded but is considered unlikely. By combining specimens from sequential days and using
243 the farthest date, we likely reduced the reportable sensitivity. Longitudinal samples from
244 individual patients were not tested to track seroconversion. The samples were not tested to
245 ascertain the presence of potential cross-reactive viruses.

246 One of the strengths of this study is the direct comparison of the three assays by parallel testing,
247 including an assay without currently published external validation. Each sample was collected
248 from a single patient, which avoids bias introduced by multiple measurements. Although our
249 specificity population was smaller, the patient samples are representative of the current local
250 circulating viruses among individuals with healthcare contacts, which lends external validity.
251 The results also include early seroconversion specimens in addition to convalescent specimens.
252 The performance characteristics of serologic assays for patients in this window period is critical
253 for clinical management decisions, particularly for acutely ill patients. We reported no false
254 positive results that may have otherwise been attributed to remote exposure with the use of a
255 post-pandemic specificity cohort.

256

257 *4.3 Conclusion*

258 We report high diagnostic accuracy and inter-test agreement for three SARS-CoV-2 serologic
259 assays. The choice of assay and its clinical utility will depend on the specific needs of individual
260 laboratories and the local public health conditions. External validation of serologic assays is
261 critical to ensure high diagnostic accuracy and appropriate utilization of critical resources.

262

263 **Funding:** This research did not receive any specific grant from funding agencies in the public,
264 commercial, or not-for-profit sectors.

265

266 **Declarations of Interest:** None.

267 **References**

- 268 [1] COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns
269 Hopkins University. 2020. <https://coronavirus.jhu.edu/map.html>. [Accessed July 12, 2020].
- 270 [2] Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA.
271 2020;323(22):2249–2251. doi:10.1001/jama.2020.8259
- 272 [3] Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, Zhou Q, Ye H, Ma Y, Li H, Wei X, Cai
273 P, Ma W. Antibody Detection and Dynamic Characteristics in Patients with COVID-19. Clin
274 Infect Dis. 2020 Apr 19. doi: 10.1093/cid/ciaa461
- 275 [4] Infectious Disease Society of America. COVID-19 Antibody Testing Primer. May 2020.
276 [https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-covid-19-antibody-](https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-covid-19-antibody-testing-primer.pdf)
277 [testing-primer.pdf](https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-covid-19-antibody-testing-primer.pdf). [Accessed July 12, 2020].
- 278 [5] Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, George KS, Smith TC, Bertuzzi S.
279 Report from the American Society for Microbiology COVID-19 International Summit, 23 March
280 2020: Value of Diagnostic Testing for SARS–CoV-2/COVID-19. mBio, March 2020, 11(2),
281 [e00722-20]. <https://doi.org/10.1128/mBio.00722-20>
- 282 [6] Food and Drug Administration. In Vitro Diagnostics EUAs. [https://www.fda.gov/medical-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas)
283 [devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas)
284 [devices/vitro-diagnostics-euas](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas). [Accessed June 28, 2020].
- 285 [7] La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2
286 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro
287 diagnostic assays. Reprod Biomed Online. 2020 Jun 14. doi: 10.1016/j.rbmo.2020.06.001
- 288 [8] Tré-Hardy M, Wilmet A, Beukinga I, Dogné J-M, Douxfils J, Blairon L. Validation of a
289 chemiluminescent assay for specific SARS-CoV-2 antibody. Clinical Chemical Laboratory
290 Medicine. 2020 May 25. doi: 10.1515/cclm-2020-0594.
- 291 [9] Plebani M, Padoan A, Negrini D, Carpinteri B, Sciacovelli L. Diagnostic performances and
292 thresholds: The key to harmonization in serological SARS-CoV-2 assays? Clin Chim Acta. 2020
293 Oct;509:1-7. doi: 10.1016/j.cca.2020.05.050
- 294 [10] Ekelund O, Ekblom K, Somajo S, Pattison-Granberg J, Olsson K, Petersson A. High-
295 throughput immunoassays for SARS-CoV-2, considerable differences in performance when
296 comparing three methods. medRxiv. May 26, 2020. doi:
297 <https://doi.org/10.1101/2020.05.22.20106294>

- 298 [11] Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, et al. Clinical And
299 Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing
300 IgG In Covid-19 Patients Semiquantitatively. *bioRxiv*. 2020;25:2000082–35.
- 301 [12] Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S,
302 Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Strassl R, Wagner OF, Binder
303 CJ, Haslacher H. Side by side comparison of three fully automated 1 SARS-CoV-2 antibody
304 assays with a focus on specificity. *medRxiv*. June 9, 2020. doi:
305 <https://doi.org/10.1101/2020.06.04.20117911>
- 306 [13] Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B. Different Longitudinal
307 Patterns of Nucleic Acid and Serology Testing Results Based on Disease Severity of COVID-19
308 Patients *Emerg Microbes Infect*. 2020 Dec;9(1):833-836. doi: 10.1080/22221751.2020.1756699.
- 309 [14] Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J, Hu J, Xu W, Zhang Y, Lv F, Su K, Zhang F,
310 Gong J, Wu B, Liu X, Li J, Qiu J, Chen J, Huang A. Clinical and immunological assessment of
311 asymptomatic SARS-CoV-2 infections. *Nat Med* (2020). [https://doi.org/10.1038/s41591-020-](https://doi.org/10.1038/s41591-020-0965-6)
312 [0965-6](https://doi.org/10.1038/s41591-020-0965-6)
- 313 [15] Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A,
314 Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Dittrich S, Emperador D, Hooft
315 L, Leeflang MMG, Van den Bruel A. Antibody tests for identification of current and past
316 infection with SARS-CoV-2. *Cochrane Database Syst Rev* 2020 Jun 25;6:CD013652. doi:
317 10.1002/14651858.CD013652
- 318 [16] Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth
319 CW. Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. *Clin Chem*. 2020 Jun
320 2:hvaa132. doi: 10.1093/clinchem/hvaa132
- 321 [17] Zhao R, Li M, Song H, Chen J, Ren W, Feng Y, Gao GF, Song J, Peng Y, Su B, Guo X,
322 Wang Y, Chen J, Li J, Sun H, Bai Z, Cao W, Zhu J, Zhang Q, Sun Y, Sun S, Mao X, Su J, Chen
323 X, He A, Gao W, Jin R, Jiang Y, Sun L. Early detection of SARS-CoV-2 antibodies in COVID-
324 19 patients as a serologic marker of infection. *Clin Infect Dis*. 2020. doi:
325 10.1093/cid/ciaa523.May1pii:ciaa523
- 326 [18] Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, Caya C, Semret
327 M, Quach C, Libman M, Mazzola L, Sacks JA, Dittrich S, Papenburg J. Serodiagnostics for

- 328 Severe Acute Respiratory Syndrome–Related Coronavirus-2: A Narrative Review. *Ann Intern*
329 *Med.* 2020 Jun 4. M20-2854. doi: 10.7326/M20-2854
- 330 [19] Jaaskelainen AJ, Kuivanen S, Kekalainen E, Ahava MJ, Loginov R, Kallio-Kokko H,
331 Vapalahti O, Jarva H, Kurkela S, Lappalainen M. Performance of six SARS-CoV-2
332 immunoassays in comparison with microneutralisation. *J Clin Virol.* 2020 Aug;129:104512. doi:
333 10.1016/j.jcv.2020.104512
- 334 [20] Espejo AP, Akgun Y, Al Mana AF, Tjendra Y, Millan NC, Gomez-Fernandez C, Cray C.
335 Review of Current Advances in Serologic Testing for COVID-19. *Am J Clin Pathol.* 2020 June
336 25;aqaa112. doi: 10.1093/ajcp/aqaa112

337 TABLE 1. Attributes for the evaluated serologic assays

338

	Roche	DiaSorin	Beckman
Assay method	Electro CLIA, Total Ab	Indirect CLIA, IgG	CLIA, IgG
Antigen	Nucleocapsid protein	S1/S2 protein	S1 protein RBD
Specimen type	Serum, Plasma	Serum, Plasma	Serum, Plasma
Total volume	250 μ L	170 μ L	250 μ L
Result units	Cutoff Index (COI)	Arbitrary Unit (AU)/mL	Signal/Cutoff (S/CO)
Positive cutoff	≥ 1.0 COI	≥ 15.0 AU/mL	≥ 1.0 S/CO
Equivocal cutoff	None	None	≥ 0.8 and < 1.0 S/CO
Throughput	300 samples per hour	170 samples per hour	400 samples per hour

Abbr.: Ab, Antibody; CLIA, Chemiluminescent Immunoassay; RBD, Receptor Binding Domain

339

340 TABLE 2. Patient demographics by PCR status

341

	Total	PCR (+)			PCR (-)
		0-6 days	7-13 days	14+ days	Total
Number of patients, n	113	17	17	17	62
Median age in years (IQR)	59 (43-72)	71 (52-77)	64 (42-74)	64 (55-69)	53 (35-70)
Female, n (%)	69 (61)	12 (71)	9 (53)	9 (53)	39 (63)

342

343 TABLE 3. Performance characteristics of each platform by PCR status

344

	PCR (+), n				PCR (-), n
	0-6 days	7-13 days	14+ days	Total	Total
Roche					
Reactive	10	16	17	43	0
Non-reactive	7	1	0	8	62
PPA, % (95% CI)	59 (33-82)	94 (71-99)	100 (80-100)	84 (71-93)	
PNA, % (95% CI)	100 (94-100)	100 (94-100)	100 (94-100)	100 (94-100)	
DiaSorin					
Positive	10	15	17	42	0
Negative	7	2	0	9	62
PPA, % (95% CI)	59 (33-82)	88 (64-99)	100 (80-100)	82 (69-92)	
PNA, % (95% CI)	100 (94-100)	100 (94-100)	100 (94-100)	100 (94-100)	
Beckman					
Reactive	11	16	17	44	0
Non-reactive	6 ^a	1	0	7	62
PPA, % (95% CI)	65 (38-86)	94 (71-99)	100 (80-100)	86 (74-94)	
PNA, % (95% CI)	100 (94-100)	100 (94-100)	100 (94-100)	100 (94-100)	

Abbr.: PPA, percent positive agreement; PNA, percent negative agreement

^a Includes 1 equivocal result

345

346 TABLE 4. Serologic assay comparison

347


		DiaSorin (n)		Beckman (n)	
		(+)	(-)	(+)	(-)
Roche (n)	(+)	41	2	42	1
	(-)	1	69	3	68
	K ^a	0.94 (0.88-1.0, 0.032)		0.93 (0.86-1.0, 0.036)	
Beckman (n)	(+)	42	2		
	(-)	0	69		
	K ^a	0.96 (0.91-1.0, 0.026)			

^a Fleiss kappa (95% CI, SE)


348

349 FIGURE 1. Quantitative results for each assay by days post positive PCR

Roche



Diasorin



Beckman

